JNJ

186.36

+0.12%↑

ABT

125.21

+1.2%↑

TMO

565.31

+0.06%↑

ISRG

538.51

-1.01%↓

DHR

214.15

0%↓

JNJ

186.36

+0.12%↑

ABT

125.21

+1.2%↑

TMO

565.31

+0.06%↑

ISRG

538.51

-1.01%↓

DHR

214.15

0%↓

JNJ

186.36

+0.12%↑

ABT

125.21

+1.2%↑

TMO

565.31

+0.06%↑

ISRG

538.51

-1.01%↓

DHR

214.15

0%↓

JNJ

186.36

+0.12%↑

ABT

125.21

+1.2%↑

TMO

565.31

+0.06%↑

ISRG

538.51

-1.01%↓

DHR

214.15

0%↓

JNJ

186.36

+0.12%↑

ABT

125.21

+1.2%↑

TMO

565.31

+0.06%↑

ISRG

538.51

-1.01%↓

DHR

214.15

0%↓

Search

Penumbra Inc

Open

BrancheGesundheitswesen

234.92 3.97

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

225.1

Max

235.07

Schlüsselkennzahlen

By Trading Economics

Einkommen

6M

45M

Verkäufe

15M

339M

KGV

Branchendurchschnitt

65.78

37.003

Gewinnspanne

13.336

Angestellte

4,500

EBITDA

1.9M

51M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+39.04% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

758M

9.7B

Vorheriger Eröffnungskurs

230.95

Vorheriger Schlusskurs

234.92

Nachrichtenstimmung

By Acuity

50%

50%

156 / 373 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Penumbra Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Nov. 2025, 21:44 UTC

Ergebnisse

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3. Nov. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3. Nov. 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3. Nov. 2025, 23:28 UTC

Ergebnisse

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3. Nov. 2025, 23:24 UTC

Ergebnisse

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. Nov. 2025, 23:14 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

3. Nov. 2025, 23:14 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3. Nov. 2025, 23:12 UTC

Ergebnisse

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. Nov. 2025, 23:09 UTC

Ergebnisse

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3. Nov. 2025, 23:09 UTC

Ergebnisse

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3. Nov. 2025, 23:09 UTC

Ergebnisse

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3. Nov. 2025, 23:06 UTC

Market Talk
Ergebnisse

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3. Nov. 2025, 22:36 UTC

Market Talk
Ergebnisse

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3. Nov. 2025, 22:31 UTC

Ergebnisse

Franco-Nevada 3Q EPS $1.49 >FNV

3. Nov. 2025, 22:31 UTC

Ergebnisse

Franco-Nevada 3Q Rev $487.7M >FNV

3. Nov. 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3. Nov. 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks Agrees to Sell Stake in China Business -- WSJ

3. Nov. 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3. Nov. 2025, 21:54 UTC

Market Talk
Ergebnisse

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3. Nov. 2025, 21:54 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

3. Nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Nov. 2025, 21:49 UTC

Ergebnisse

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3. Nov. 2025, 21:40 UTC

Ergebnisse

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3. Nov. 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3. Nov. 2025, 21:19 UTC

Ergebnisse

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3. Nov. 2025, 21:11 UTC

Akquisitionen, Fusionen, Übernahmen

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3. Nov. 2025, 21:11 UTC

Ergebnisse

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3. Nov. 2025, 21:07 UTC

Ergebnisse

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3. Nov. 2025, 21:05 UTC

Ergebnisse

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. Nov. 2025, 21:05 UTC

Ergebnisse

Palantir Technologies 3Q Net $475.6M >PLTR

Peer-Vergleich

Kursveränderung

Penumbra Inc Prognose

Kursziel

By TipRanks

39.04% Vorteil

12-Monats-Prognose

Durchschnitt 314.5 USD  39.04%

Hoch 350 USD

Tief 285 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Penumbra Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

10

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

288.28 / 292.9394Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

156 / 373 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat